Northern Trust Corp grew its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 36.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 643,157 shares of the company's stock after purchasing an additional 171,374 shares during the period. Northern Trust Corp owned approximately 0.94% of EyePoint Pharmaceuticals worth $4,792,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Barclays PLC increased its position in EyePoint Pharmaceuticals by 410.4% during the 3rd quarter. Barclays PLC now owns 245,045 shares of the company's stock worth $1,959,000 after purchasing an additional 197,033 shares during the period. abrdn plc acquired a new position in EyePoint Pharmaceuticals during the 4th quarter worth approximately $1,719,000. Raymond James Financial Inc. acquired a new position in EyePoint Pharmaceuticals during the 4th quarter worth approximately $76,000. Rhumbline Advisers increased its position in EyePoint Pharmaceuticals by 16.1% during the 4th quarter. Rhumbline Advisers now owns 89,560 shares of the company's stock worth $667,000 after purchasing an additional 12,443 shares during the period. Finally, Corebridge Financial Inc. increased its position in EyePoint Pharmaceuticals by 21.6% during the 4th quarter. Corebridge Financial Inc. now owns 32,499 shares of the company's stock worth $242,000 after purchasing an additional 5,765 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have issued reports on EYPT shares. HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Mizuho dropped their target price on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research report on Friday, May 16th. Chardan Capital dropped their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen upgraded EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, EyePoint Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $25.38.
View Our Latest Report on EYPT
EyePoint Pharmaceuticals Stock Up 1.4%
Shares of EYPT traded up $0.08 on Friday, reaching $5.68. The stock had a trading volume of 368,862 shares, compared to its average volume of 814,541. The firm has a market capitalization of $390.85 million, a PE ratio of -2.84 and a beta of 1.58. The firm has a 50-day moving average of $5.82 and a 200 day moving average of $7.15. EyePoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $13.99.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65). The business had revenue of $24.50 million for the quarter, compared to analysts' expectations of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. On average, sell-side analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.
About EyePoint Pharmaceuticals
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
See Also
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
